We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
+16.54%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$304M
AUM Growth
+$14.8M
Cap. Flow
-$12.3M
Cap. Flow %
-4.05%
Top 10 Hldgs %
63.35%
Holding
64
New
3
Increased
5
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$19.4M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$16M
3
TVTX icon
Travere Therapeutics
TVTX
+$11.5M
4
SWTX
SpringWorks Therapeutics
SWTX
+$8.83M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.22M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$15.8M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$15.1M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14.1M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$12.1M
5
ARGX icon
argenx
ARGX
+$8.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.74%
2 Materials 7.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GATEW
51
DELISTED
Marblegate Acquisition Corp. Warrant
GATEW
$16K 0.01%
735,000
– –
LVRAW
52
DELISTED
Levere Holdings Corp. Warrant
LVRAW
$14K ﹤0.01%
274,999
– –
SNRHW
53
DELISTED
Senior Connect Acquisition Corp. I Warrant
SNRHW
$10K ﹤0.01%
1,014,000
– –
WPCB.WS
54
DELISTED
Warburg Pincus Capital Corporation I-B Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
WPCB.WS
$8K ﹤0.01%
125,000
– –
TMAC.WS
55
DELISTED
The Music Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
TMAC.WS
$3K ﹤0.01%
75,250
– –
WPCA.WS
56
DELISTED
Warburg Pincus Capital Corporation I-A Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
WPCA.WS
$1K ﹤0.01%
14,999
– –
PTGX icon
57
Protagonist Therapeutics
PTGX
$9.06B
– –
-735,126
Closed -$5.82M
RARE icon
58
Ultragenyx Pharmaceutical
RARE
$2.88B
– –
-203,200
Closed -$12.1M
SRPT icon
59
Sarepta Therapeutics
SRPT
$1.82B
– –
-211,000
Closed -$15.8M
MRTX
60
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-210,200
Closed -$14.1M
GBT
61
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-474,000
Closed -$15.1M
IPOF.WS
62
DELISTED
Social Capital Hedosophia Holdings Corp. VI Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
IPOF.WS
– –
-671,000
Closed -$322K
EQD.WS
63
DELISTED
Equity Distribution Acquisition Corp. Warrants, each whole warrant exercisable for one share of Clas
EQD.WS
– –
-669,000
Closed -$69K
1 2
3

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Finepoint Capital held 64 positions worth $304M, up 5.1% from $289M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Finepoint Capital withdrew a net $12.3M in Q3 2022, closing 7 positions and reducing 7 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $15.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier, followed by Materials.

Against the trend, Finepoint Capital opened a new position in Arvinas worth $17.8M.

  • Finepoint Capital's largest Q3 2022 buy was Arvinas: 399,000 shares worth $17.8M.
  • Finepoint Capital added most to Travere Therapeutics in Q3 2022, an estimated $11.5M increase.
  • Finepoint Capital's biggest Q3 2022 reduction was argenx, cutting an estimated $8.9M.
  • Finepoint Capital fully exited Sarepta Therapeutics in Q3 2022, selling an estimated $15.8M.
  • Finepoint Capital's ten largest holdings make up 63% of its $304M portfolio in Q3 2022.
  • Finepoint Capital opened 3 new positions and closed 7 in Q3 2022.
  • Finepoint Capital's portfolio value rose 5.1% quarter-over-quarter to $304M.

Based on Finepoint Capital's 13F filing for Q3 2022, filed 10 Nov 2022.